Related Experiment Video

Updated: May 16, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Genotype-selective combination therapies for melanoma identified by high-throughput drug screening

Matthew A Held1, Casey G Langdon, James T Platt

  • 1Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.

Cancer Discovery
|December 15, 2012
PubMed
Abstract

Insights

Combinatorial drug screening identified effective treatments for BRAF and RAS-mutant melanomas, including those resistant to targeted therapies. This approach offers new strategies to overcome drug resistance in melanoma.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Targeted monotherapy for cancer faces challenges due to resistance and partial responses.
  • Genotype-specific drug combinations are not well-established for cancer treatment.
  • Developing systematic approaches for identifying effective drug combinations is crucial.

Purpose of the Study:

  • To discover efficacious pairwise drug combinations for melanoma treatment using combinatorial screening.
  • To identify drug combinations effective against BRAF and RAS-mutant melanomas, including vemurafenib-resistant cases.
  • To explore strategies for overcoming resistance phenotypes in melanoma.

Main Methods:

  • Pairwise combinations of small-molecule inhibitors were tested on early-passage melanoma cultures.
  • Combinatorial drug screening was employed to assess treatment efficacy.
  • In vitro and in vivo studies (xenografts) were used to validate findings.

Main Results:

  • Several inhibitor combinations showed efficacy in BRAF-mutant melanomas, including those resistant to vemurafenib.
  • Inhibiting EGF receptor and AKT sensitized vemurafenib-resistant BRAF-mutant melanomas.
  • RAS-mutant melanomas, while more resistant to some combinations, responded to statins and CDK inhibitors.
  • In vivo xenografts demonstrated enhanced benefit and tolerability of a mutant RAS-selective combination.

Conclusions:

  • Drug combinatorial screening successfully identified effective combinations for BRAF- and RAS-mutant melanomas.
  • Proposed mechanisms explain the interactions of identified drug combinations.
  • A mutant RAS-selective combination showed enhanced benefit and tolerability in vivo, addressing a clinical gap.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...